Stock of the Day

September 11, 2026

UnitedHealth Group (UNH)

$387.69
-$5.37 (-1.4%)
Market Cap: $352.81B

About UnitedHealth Group

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota.

UnitedHealth Group Bull Case

Here are some ways that investors could benefit from investing in UnitedHealth Group:

  • UnitedHealth Group recently reported a significant earnings beat in its second quarter, delivering $6.38 in earnings per share compared to the analyst consensus of $4.94, which signals a strong operational turnaround and validates the company's recovery trajectory.
  • The company is investing nearly $1.5 billion in artificial intelligence to expand Optum Insight’s software capabilities, a strategic move aimed at improving operating efficiency and creating new growth opportunities in the healthcare technology sector.
  • UnitedHealth Group is removing prior-authorization requirements for a broad range of healthcare services starting October 1, part of a plan to eliminate such requirements for 30% of services by the end of 2026, which could reduce administrative burdens and improve patient and provider satisfaction.
  • With a current stock price of $387.69, the stock trades at a P/E ratio of 24.95, which is supported by a consensus rating of Moderate Buy and a target price of $455.92, suggesting potential upside for investors who believe in the sustainability of the recent performance improvements.
  • Institutional investors are showing renewed confidence, with firms like Baird Financial Group Inc. increasing their holdings by 41.6% and NewEdge Advisors LLC boosting their positions by 14.0% in the second quarter, indicating strong professional interest in the stock's recovery.

UnitedHealth Group Bear Case

Investors should be bearish about investing in UnitedHealth Group for these reasons:

  • The partial sale of the Florida WellMed primary-care clinic network to TPG has raised concerns among investors, as these operations have been associated with recent profit problems in Optum Health, potentially signaling a need for outside capital during the turnaround.
  • UnitedHealth Group faces continued pressure from high medical-cost growth, a trend highlighted by peers like CVS Health, which threatens the margins of its commercial insurance business and adds uncertainty to its profitability outlook.
  • The stock trades at a substantial valuation premium compared to some managed-care peers despite having slower revenue growth, making it more sensitive to any disappointing guidance or execution issues in the coming quarters.
  • CEO Patrick Conway has been selling shares, including a recent sale of 1,169 shares at an average price of $390.00, which may be interpreted by some investors as a lack of confidence in the stock's near-term upside.
  • Broader healthcare-sector weakness and specific concerns about the sustainability of the Optum turnaround have contributed to selling pressure, with the stock recently dipping more than the broader market on days of negative sentiment.
← Previous Stock of the Day

Recent News